Company Encyclopedia
View More
name
Avadel Pharma
AVDL.US
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
4.499 T
AVDL.USMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking20/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-0.32%D
    • Profit Margin-0.11%D
    • Gross Margin105.31%A
  • Growth ScoreA
    • Revenue YoY79.88%A
    • Net Profit YoY99.62%A
    • Total Assets YoY26.03%A
    • Net Assets YoY31.56%A
  • Cash ScoreC
    • Cash Flow Margin-89394.60%E
    • OCF YoY79.88%A
  • Operating ScoreA
    • Turnover1.39A
  • Debt ScoreC
    • Gearing Ratio50.75%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Is Avadel Pharmaceuticals Still Attractive After a 113.4% One Year Surge in 2025?

    Avadel Pharmaceuticals has surged 113.4% over the past year, driven by investor confidence in its sleep medicine franchise. Despite recent gains, it is considered undervalued by 34.1% according to a Discounted Cash Flow analysis, suggesting a potential intrinsic value of $32.36 per share. However, its Price to Sales ratio indicates it may be slightly overvalued compared to industry peers. Investors are encouraged to consider their own narratives and financial forecasts when evaluating the stock's potential.

    Simplywall·
    US
    AVDL
    -0.07%
    Simplywall·
    US
    AVDL
    -0.07%

    REG - Citadel Group Avadel Pharma plc - Form 8.3 - Avadel Pharmaceuticals plc

    Citadel Group disclosed its opening position under Rule 8.3 of the Irish Takeover Panel Act, 1997, regarding Avadel Pharmaceuticals plc. The disclosure includes interests and short positions in Avadel's securities, with Citadel owning 1.2% and holding short positions of 1.05%. The disclosure details various transactions, including purchases and sales of common stock, and highlights the company's interests in stock-settled derivatives.

    London Stock Exchange·
    US
    AVDL
    -0.07%
    London Stock Exchange·
    US
    AVDL
    -0.07%

    REG - Geode Capital Mgmnt Avadel Pharma plc - Form 8.3 - Avadel Pharmaceuticals plc

    Geode Capital Management LLC disclosed its opening position in Avadel Pharmaceuticals plc under Rule 8.3 of the Irish Takeover Panel Act, 1997. The disclosure includes interests and short positions in USD 0.01 ordinary shares, totaling 2,192,395 shares, representing 2.23%. The disclosure also details a purchase of 1,888 shares at $21.35 per unit. No indemnity or option arrangements were reported.

    London Stock Exchange·
    US
    AVDL
    -0.07%
    London Stock Exchange·
    US
    AVDL
    -0.07%

    REG - Tudor Cap Eur LLP Avadel Pharma plc - Form 8.3 Avadel Pharmaceuticals Plc

    Tudor Capital Europe LLP disclosed its interests and short positions in Avadel Pharmaceuticals Plc under Rule 8.3 of the Irish Takeover Panel Act, 1997. The disclosure includes details of securities owned, cash-settled derivatives, and stock-settled derivatives. No indemnity or option arrangements were reported. The disclosure was made on December 5, 2025, by Ben Kitchener.

    London Stock Exchange·
    US
    AVDL
    -0.07%
    London Stock Exchange·
    US
    AVDL
    -0.07%

    REG - Irish Takeover Panel - Disclosure Table

    The Irish Takeover Panel has disclosed that Mural Oncology plc, Avadel Pharmaceuticals plc, and Permanent TSB Group Holdings plc are in an offer period. Mural Oncology's offeror is XOMA Royalty Corporation, and Avadel Pharmaceuticals' offeror is Alkermes plc. Permanent TSB Group Holdings has no identified offeror. This disclosure is part of the rules of the Irish Takeover Panel, with no specific Rule 2.6(a) deadlines provided for these companies.

    London Stock Exchange·
    US
    MURA
    0.00%
    US
    AVDL
    -0.07%
    London Stock Exchange·
    US
    MURA
    0.00%
    US
    AVDL
    -0.07%
    © 2025 Longbridge｜Disclaimer